Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941610 · ClinicalTrials.gov registry record · NA
An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity
A NA study of Skin Laxity, sponsored by Erchonia Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06941610: Recruiting NA study of Skin Laxity, sponsored by Erchonia Corporation.
NCT06941610 is a NA study of Skin Laxity that is actively recruiting participants, run by Erchonia Corporation. The registered enrollment target is 35 participants, below the 187-participant average among 10 other Skin Laxity trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06941610, a NA study of Skin Laxity, is actively recruiting participants, sponsored by Erchonia Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical study is to determine the effectiveness of the Erchonia® GVS in improving the appearance of skin laxity on the abdominal region.
Primary Outcome
Reviewers will be blinded to post-treatment (12 weeks) vs. baseline untreated area. The order in which images will be presented will be randomized. Reviewers will be asked to select the baseline photos for each subject photo series and record selections on a data collection form. Success is defined as at least 2 of the 3 blinded evaluators correctly identifying a subject's pre-treatment and post-treatment (study endpoint) photographs for 80% or more of subjects.
Conditions Studied
Interventions
- DEVICE Erchonia GVS Laser
Study Locations (1)
Florida
- Cesar A. Lara M.D. Weight Loss & Wellness - Dunedin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2026-11-01 |
| Phase | NA |
What NCT06941610 shows while recruiting
NCT06941610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 187-participant average among 10 other Skin Laxity trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Skin Laxity appearing as the primary indexed condition, and to 1 intervention - of which Erchonia GVS Laser is the first listed.
NCT06941610 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06941610 about?
NCT06941610 is a clinical study titled "An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity". The purpose of this clinical study is to determine the effectiveness of the Erchonia® GVS in improving the appearance of skin laxity on the abdominal region.
What is the current status of trial NCT06941610?
This trial is currently recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2025-05-30. Estimated completion is 2026-11-01.
What conditions does trial NCT06941610 study?
This clinical trial studies the following conditions: Skin Laxity.
What interventions are being tested in trial NCT06941610?
The interventions under investigation include: Erchonia GVS Laser (DEVICE).
Who is sponsoring clinical trial NCT06941610?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941610 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Laxity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06941610's enrollment target sits among peer trials
35 6th of 10 higher than 5 of 10 other Skin Laxity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Laxity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging
RECRUITING · NA
-
Evaluation of Fractional Ablative Laser Treatment for Skin Conditions
RECRUITING · NA
-
AV-23-001 AVAVA MIRIA Pilot Study
ACTIVE NOT RECRUITING · NA
-
Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System
ACTIVE NOT RECRUITING · NA
-
Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies
ACTIVE NOT RECRUITING · NA
-
Feasibility Study: Heavy Water Tissue Labeling Protocol
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI